INSMED Inc. Files 8-K with Financials and Exhibits

Ticker: INSM · Form: 8-K · Filed: 2025-06-13T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, financials, regulation-fd

TL;DR

INSMED filed an 8-K on 6/11, check it for financials and other updates.

AI Summary

On June 11, 2025, INSMED Inc. filed an 8-K report to disclose information under Regulation FD and other events. The filing includes financial statements and exhibits, with the report being made public on June 13, 2025. The company is based in Bridgewater, New Jersey, and operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing provides updated information and financial details for INSMED Inc., which is important for investors and stakeholders to assess the company's current status and performance.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for disclosure purposes and does not appear to contain any significant negative news or events.

Key Players & Entities

FAQ

What specific items are being disclosed in this 8-K filing?

This 8-K filing is intended to cover disclosures under Regulation FD, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on June 11, 2025.

What is INSMED Inc.'s primary business sector?

INSMED Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.

Where are INSMED Inc.'s principal executive offices located?

INSMED Inc.'s principal executive offices are located at 700 US Highway 202/206, Bridgewater, New Jersey, 08807.

What is the filing date for this 8-K report?

This 8-K report was filed as of June 13, 2025.

From the Filing

0001140361-25-022375.txt : 20250613 0001140361-25-022375.hdr.sgml : 20250613 20250613082111 ACCESSION NUMBER: 0001140361-25-022375 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20250611 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250613 DATE AS OF CHANGE: 20250613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 251044792 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 8-K 1 ny20050461x3_8k.htm FORM 8-K false INSMED Inc 0001104506 NASDAQ 0001104506 2025-06-11 2025-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia   000-30739   54-1972729 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.) 700 US Highway 202/206 Bridgewater , New Jersey   08807 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: ( 908 ) 977-9900 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]   ITEM 8.01 — Other Events. On June 11 , 2025, Insmed Incorporated (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Leerink Partners LLC as representatives of the several underwriters (the “Underwriters”), pursuant to which, subject to satisfaction of the conditions set forth therein, the Company has agreed to sell to the Underwriters, and the Underwriters have agreed to purchase from the Company, 7,812,500 shares (the “Firm Shares”) of the common stock, par value $0.01 per share, of the Company (the “Common Stock”). The Company also granted the Underwriters a 30-day option to purchase up to an additional 1

View on Read The Filing